WELL Health Technologies Corp. (WELL.TO)
| Previous close | 3.8800 |
| Open | 3.8800 |
| Bid | 4.1500 x N/A |
| Ask | 4.1600 x N/A |
| Day's range | 3.8800 - 4.1700 |
| 52-week range | 3.4100 - 5.2600 |
| Volume | |
| Avg. volume | 899,458 |
| Market cap | 1.022B |
| Beta (5Y monthly) | 1.28 |
| PE ratio (TTM) | 34.67 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
WELL Health Enters into Automatic Share Purchase Plan
WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a company focused on positively impacting health outcomes by leveraging technology to empower practitioners and their patients globally, announced today that it has entered into an automatic share purchase plan ("ASPP") with a broker in order to facilitate repurchases of the Company's common shares ("Common Shares") under its previously announced normal course issuer bid ("NCIB").
- PR Newswire
WELL Health Announces Approval of Normal Course Issuer Bid
WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL" or the "Company"), a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that its Notice of Intention to Make a Normal Course Issuer Bid ("NCIB") filed with the Toronto Stock Exchange ("TSX") has been approved. The NCIB is a renewal of its NCIB that expired on June 4, 2024.
- GlobeNewswire
HEALWELL AI Participates in Leading-Edge Research on Chronic Kidney Disease Highlighting the Potential of its AI Powered Clinical Co-Pilot
HEAWELL AI’s Clinical Co-Pilot technology participated in recently published evidence showing the integration of a highly accurate machine model for Chronic Kidney Disease (“CKD”) progression when paired with Electronic Health Record (“EHR”) linked clinical decision support, improves guideline-recommended testing in patients with CKD.HEALWELL’s subsidiary Khure Health (“Khure”) co-authored an abstract that was published this month in the American Journal of Kidney Diseases, providing evidence of
